Dimerix Limited (ASX:DXB)
Australia · Delayed Price · Currency is AUD | Market Cap | 312.07M |
| Revenue (ttm) | 737.87K |
| Net Income (ttm) | -23.31M |
| Shares Out | 600.14M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,243,512 |
| Average Volume | 1,753,296 |
| Open | 0.5100 |
| Previous Close | 0.5100 |
| Day's Range | 0.5000 - 0.5200 |
| 52-Week Range | 0.3000 - 0.7850 |
| Beta | 0.53 |
| RSI | 49.76 |
| Earnings Date | Aug 28, 2025 |
About Paramount Global
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia. [Read more]
Financial Performance
In 2024, Dimerix's revenue was 583,478, an increase of 1486.10% compared to the previous year's 36,787. Losses were -17.08 million, 23.7% more than in 2023.
Financial StatementsNews
Biotech Dimerix lands $940m licensing deal for kidney drug sales
The Melbourne-based company says it has landed one of the biggest licensing deals in Australian biotech history.